Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Horizon Discovery, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the signing of a commercial license agreement.

Horizon Discovery

Image Credit: Horizon Discovery

Under the terms of the agreement, Horizon’s CHOSOURCE™ platform will be used in combination with Rentschler Biopharma’s novel in-house process for cell line development for difficult-to-express proteins.

Horizon’s gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cGMP-compliant cell line will complement Rentschler Biopharma’s existing service offering, providing a royalty-free, state-of-the-art alternative for the production of highly complex proteins. This will support researchers from early drug development through commercial manufacturing.

By entering into the agreement, Horizon and Rentschler Biopharma aim to empower organizations of all sizes, from large pharmaceutical companies to clinical-stage biotechs and early-stage startups, to drive efficiencies in biotherapeutic manufacturing.

Rentschler Biopharma’s integrated platform process, together with Horizon’s cell line, will provide innovative and tailored solutions to translate complex medical research into outstanding biopharmaceuticals.

This will elevate the standard of protein expression and allow clients to access a robust and flexible approach for designer protein therapeutics, from concept to market.

At Rentschler Biopharma, we consistently strive to offer our clients optimal and truly integrated solutions across the entire value chain. We achieve this by our own means as well as through strong partnerships. The new collaboration with Horizon, a very renowned company in the area of cell line engineering with an outstanding track record, significantly broadens our fit-for-purpose approach.”

Dr. Frank Mathias, CEO of Rentschler Biopharma

We are very pleased to be working with such a well-respected organization within the field of biomanufacturing. This agreement brings together two world-class companies in biomanufacturing and further supports our ethos of enabling access to the CHOSOURCE platform in such a way as to empower organizations of all sizes to drive efficiencies in development and production of biotherapeutics.”

Terry Pizzie, CEO of Horizon Discovery

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2024, March 27). Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins. News-Medical. Retrieved on May 26, 2024 from https://www.news-medical.net/news/20200519/Rentschler-Biopharma-licenses-Horizon-Discoverye28099s-CHOSOURCE-platform-to-complement-cell-line-development-offering-for-difficult-to-express-proteins.aspx.

  • MLA

    Revvity. "Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins". News-Medical. 26 May 2024. <https://www.news-medical.net/news/20200519/Rentschler-Biopharma-licenses-Horizon-Discoverye28099s-CHOSOURCE-platform-to-complement-cell-line-development-offering-for-difficult-to-express-proteins.aspx>.

  • Chicago

    Revvity. "Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins". News-Medical. https://www.news-medical.net/news/20200519/Rentschler-Biopharma-licenses-Horizon-Discoverye28099s-CHOSOURCE-platform-to-complement-cell-line-development-offering-for-difficult-to-express-proteins.aspx. (accessed May 26, 2024).

  • Harvard

    Revvity. 2024. Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins. News-Medical, viewed 26 May 2024, https://www.news-medical.net/news/20200519/Rentschler-Biopharma-licenses-Horizon-Discoverye28099s-CHOSOURCE-platform-to-complement-cell-line-development-offering-for-difficult-to-express-proteins.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PerkinElmer unveils industry-first cell analysis solution to streamline cell and gene therapy research and manufacturing